We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Molecular Methods Differentiate Breast Cancers

By LabMedica International staff writers
Posted on 01 May 2012
Molecular technology has been used to the reclassify the manifestations of breast cancer into a multiplicity of different diseases. More...


By analyzing the DNA and ribonucleic acid (RNA) from breast cancer tumors, it is proposed that what are called breast cancer are in fact at least 10 different diseases, each with its own molecular fingerprint and pattern of weak spots.

In a landmark study that promises to revolutionize diagnosis and prognosis, and pave the way for individualized, tailored treatment, British and Canadian scientists uncovered crucial new information about breast cancer. The scientists analyzed the DNA and RNA of breast tumor samples from nearly 2,000 women who had been diagnosed between 5 and 10 years ago, and for whom information about the tumor characteristics had been meticulously recorded. The teams were from the Cambridge Research Institute (UK) and British Columbia Cancer Center (Vancouver, BC, Canada).

The team performed analyses on the DNA of the tumors--for instance, the map is now annotated with copy number changes and single letter variations or single-nucleotide polymorphism, for each tumor. The scientists also conducted a detailed analysis of the tumor RNA so they can tell which genes were active in each sample. Altogether, they did this for more than 30,000 types of RNA, each corresponding to the activity of a single gene.

The study revealed the relationship between breast cancer genes and known signaling pathways, the networks that control cell growth and division. This invaluable knowledge will help identify how variants of these genes cause cancer by interfering with cell processes. The team also discovered several previously unknown genes that drive breast cancer. Each of these is a potential target for new drugs, and should boost worldwide efforts to discover and develop new treatments.

Carlos Caldas, MD, professor of Cancer Medicine at Cambridge said, "We've drilled down into the fundamental detail of the biological causes of breast cancer, and we've moved from knowing what a breast tumor looks like under a microscope to pinpointing its molecular anatomy. Our results will pave the way for doctors in the future to diagnose the type of breast cancer a woman has, the types of drugs that will work, and those that won't, in a much more precise way than is currently possible." The study was published in the April 18, 2012, online issue of Nature.

Related Links:
Cambridge Research Institute
British Columbia Cancer Center


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.